5287945
Last Update Posted: 2026-01-09
Recruiting
All Genders accepted | 18 Years + |
75 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma.
A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma.
Eligibility
Relevant conditions:
Carcinoma, Renal Cell
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Börje Haraldsson, M.D., Ph.D.
borje.haraldsson@oncorena.com
+46702679544
Data sourced from ClinicalTrials.gov